The International Exchange of Professionals - Thematic Event in Pharmaceutical Science and Technology & The 20th Annual Congress of International Drug Discovery Science & Technology 2024 was successfully held on May 22-24, 2024 at the beautiful Grand Prince Hotel Osaka Bay, Japan. It was proudly hosted by World High Technology Society, proudly supported by China Association for International Exchange of Personnel, and efficiently operated by BIT Group Global Ltd. and Shenzhen Center for International Exchange of Personnel. It integrated 3 distinct parallel meetings together, which were The 20th Annual Congress of International Drug Discovery Science and Technology (IDDST), The 11th Annual International Symposium of Drug Delivery Systems (SDDS), and The 2nd World Chemistry Congress (IWCC). Following the meticulous preparation, nearly 190 specialists from 37 countries and areas joined us in this endeavor.
The Opening Ceremony and Keynote Forum took place on the morning of the first day of the meeting, and the world-leading scientists, Dr. Muneto Mogi, Global Head of Chemistry, Novartis Biomedical Research, USA; Dr. Jeff Song, Vice President, Boehringer Ingelheim Pharmaceuticals, Inc, USA; Dr. Matthias von Herrath, Vice President and Senior Medical Officer, Novo Nordisk, USA; Dr. Diane J. Burgess, Distinguished Professor and Pfizer Distinguished Chair of Pharmaceutical Technology, University of Connecticut, USA; Dr. Anne S.J. Lesage, Chief Early Development Officer, Pharvaris GmbH, Switzerland; Dr. Antonio Cabal, Senior Director, Biology Based Modeling & Simulation, Eisai Inc., USA presented the keynote lectures. More than 120 honored guests attended those important activities. Dr. Matthias von Herrath as moderator of the two parts expressed great gratitude to the presence of all delegates, speakers and participants and particularly wished all the guests a memorable stay in Japan on behalf of the organizing committee. Eminent session speakers from various reputed companies and Universities made their resplendent presence and addressed the gathering.
As with previous editions, the cluster meeting is known for uplifting the future of the research fields by encouraging scientists and fellow researchers to present their work through oral speeches and poster presentations. Hot topics on Drug Discovery S&T, Drug Delivery Systems and Chemistry were hotly discussed and exchanged by presenters and visitors in the three-day’s diversified program. Conference organizers took the privilege of felicitating Keynote Speakers, Chair and Co-Chairs whose support made conference a great success and also thank all other attendees who contributed a lot for the smooth functioning of the Event.
Before and after the conference, we received warm support and valuable suggestions from the delegates on how to better plan and organize the next conference. With the enormous feedback from the participants and supporters, the organizing committee will have confidence and bring forth “IDDST-2025” scheduled to be held in Japan. We look forward to meeting you all next year.
The Annual Congress of International Drug Discovery Science &Technology (IDDST) initiated since 2003, it has been successfully hosted in Shanghai (China), Beijing (China), Shenzhen (China), Nanjing (China), Haikou (China), Suzhou (China), Xi’an (China), Gyeonggi (South Korea), Osaka (Japan), Boston (USA), Kyoto (Japan), Tokyo (Japan) and Amsterdam (the Netherlands) has attracted more than 10,000 participants from over 50 countries and regions in the previous 19 years. This year, the 20th Annual Congress of International Drug Discovery Science & Technology-2024 (IDDST-2024) will be held during May 22-24, 2024 at Osaka, Japan.
● Learn Global Market Trends for Drug Discovery
● Organize up to 150+ Oral Presentations on the Latest Trend
● 200+ Attendees to Exchange Ideas and Build New Networks
● Bring together 20+ Exhibitors and Posters on New Development
● Opportunities to Visit the local Natural and Cultural Landscapes
|
Dr. Matthias von Herrath, Scientific Director of the Diabetes Research Institute, University of Miami School of Medicine; Vice President, Novo Nordisk, USA |
|
Dr. Diane J. Burgess, Distinguished Professor and Pfizer Distinguished Chair of Pharmaceutical Technology, University of Connecticut, USA |
|
Dr. Jeff Song, Vice President, Boehringer Ingelheim Pharmaceuticals, Inc, USA |
|
Dr. Muneto Mogi, Global Head, Global Discovery Chemistry, Novartis Institutes for BioMedical Research (NIBR), USA |
|
Dr. Anne S.J. Lesage, Chief Early Development Officer, Pharvaris GmbH, Switzerland |
|
Dr. Antonio Cabal, Sr. Director, Biology Based Modeling & Simulation, Eisai Inc., USA |
 |
Dr. Mats Larsson, Professor, Department of Physics, Stockholm University, Sweden |
 |
Dr. Hans Keirstead, Chief Executive Officer, AIVITA Biomedical, Inc., USA |
 |
Dr. Miles Cunningham, Medical Director, Harvard Medical School, USA |
 |
Dr. Lloyd Friedman, Professor, Yale University School of Medicine, USA |
 |
Dr. Farzin Farzaneh, Chief Scientific Officer, Virocell Biologics Limited; Professor of Molecular Medicine, King’s College London, UK |
 |
Dr. Antonio Cabal, Sr. Director, Biology Based Modeling & Simulation, Eisai Inc., USA |
 |
Dr. Richard B. Krueger, Clinical Professor of Psychiatry, Columbia University, Department of Psychiatry, Vagelos College of Physicians & Surgeons, USA |
 |
Dr. George Udeani, Professor and Head, Texas A&M University, USA |
 |
Dr. Marina Komaroff, Senior Director, Biostatistics – Product Development, Noven Pharmaceuticals, Inc., USA |
 |
Dr. Yiqun Helen Li, Head of IT Lilly Biotechnology Center, Eli Lilly and Company, USA |
 |
Dr. Bradly Keck, Director, Pharmaron, USA |
 |
Dr. Andreas Seidl, Chief Operating Officer, Leukocare AG, Germany |
 |
Dr. Kun Cheng, Distinguished Professor, University of Missouri-Kansas City, USA |
 |
Dr. Raphael Serreau, Professor, Paris Saclay by Pharmacologist, University of Orleans, France |
 |
Dr. Richard Denk, Senior Consultant, Aseptic Processing & Containment, SKAN AG, Switzerland |
 |
Dr. Maria A. Miteva, Research Director, INSERM, France |
 |
Dr. Shu Ye, Professor, National University of Singapore, Singapore |
 |
Dr. Kiyoshi Nokihara, Founder CEO & CSO, HiPep Laboratories, Japan |
 |
Dr. Miriam Kidron, Chief Scientific Officer and Director, Oramed Pharmaceuticals, Israel |
 |
Dr. Frank Fan, Head of Biology, Promega Corporation, USA |
 |
Dr. Yali Dou, Professor of Medicine, University of Southern California, USA |
 |
Dr. Marcelo F. Vela, Professor of Medicine, Mayo Clinic College of Medicine and Science, USA |
 |
Dr. Dulcie A Mulholland, Professor, Department of Chemistry, University of Surrey, UK |
 |
Dr. Anne Lesage, Chief Early Development Officer, Pharvaris B.V., Switzerland |
 |
Dr. Jonathan D C Ross, Professor, University Hospital Birmingham, Whittall Street Clinic, UK |
 |
Dr. Beka Solomon, Professor, Tel-Aviv University, Israel |
 |
Dr. Gemma Budd, Director of Business Development, Nanopharm, UK |
 |
Dr. Klaus Groschner, Professor, Medical University of Graz, Austria |
 |
Dr. Elizabeth Kwong, Co-Founder & Chief Development Officer, Kwong Eureka Solutions, Canada |
 |
Dr. Eduard Korkotian, Professor, Weizmann Institute of Science, Israel |
 |
Dr. Michele Papa, Professor, University of Campania, Italy |
 |
Dr. Nathalie Wauthoz, Professor, Universite Libre de Bruxelles, Belgium |
 |
Dr. Michael Junger, Head of Medical Device, Vaxxas Nanopatch, Australia |
 |
Dr. Yuhua Li, Co-Founder, Sr. Vice President of R & D, Foresee Pharmaceuticals USA, Inc., USA |
 |
Dr. Valerie Gouon-Evans, Associate Professor, Boston University School of Medicine, USA |
 |
Dr. Nir Debotton, Director, Shenkar College of Engineering and Design, Israel |
IDDST-2024 provides an ideal platform to showcase your novel technologies and products. It is developed to offer comfort to delegates while maximizing exhibitor exposure, the coffee breaks and poster sessions will all take place in the exhibition area promoting frequent repeated opportunities for delegates to visit the exhibits.
Why Reserve a Booth at IDDST-2024
• To Meet Face-to-Face with the International Movers and Shakers
• To Meet with Key Decision Marker
• To Explore Business Opportunities
• To Spotlight Advanced Technologies and Their Scientific and Commercial Applications
• To Take Advantage of the Conference's Captive Audience and Networking Opportunities within the Exhibition Hall
  |
Exhibition Date: |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
© 2003-2024 All rights reserved by BITeomics |